Published Date: July 27, 2026
Author: HANetf
Health Care sentiment shifted meaningfully over the course of the second quarter. Biopharma’s momentum, which had cooled in the first quarter as investor attention rotated toward artificial intelligence, reasserted itself sharply in the back half of the quarter, particularly through the month of June, as a wave of M&A activity and positive clinical data presentations drew technology-oriented capital back into the sector. The Russell growth indices’ annual reconstitution also lifted biopharma’s weight within the health care benchmarks, amplifying the sub-industry’s influence on relative performance heading into the third quarter.
Biotechnology was again the standout performer, though leadership within the rally was notably narrow and concentrated in the more speculative, non-earning corner of the group, a dynamic that stands in contrast to our process’s longstanding preference for commercial-stage, earnings-generating biopharma. Medical technology remained the weakest area of the sector for a second consecutive quarter, weighed down by idiosyncratic issues among several large-cap bellwethers and lingering uncertainty over whether softer procedure volumes reflect a transient or more structural trend, though valuations have compressed to levels we consider increasingly attractive. Health care distributors, which we view as a defensive subsector insulated from broader macro and geopolitical crosscurrents, continued to benefit from steady prescription volume growth and GLP-related tailwinds.
We remain constructive on Health Care overall, and our conviction in biopharma across the market-cap spectrum remains strong. The quarter’s rally was a reminder that the sub-industry can move quickly once sentiment turns, and while a portion of that move was concentrated in lower-quality names that sit outside our process, we believe the underlying drivers remain firmly in place: improving M&A conditions, a more accommodative regulatory backdrop, and a maturing group of commercial-stage companies with genuine standalone growth prospects.
During the quarter, the Harbor Health Care UCITS ETF (the “portfolio”) returned +13.82% (gross, preliminary), underperforming the Russell 3000 Growth Health Care Index (the “index”), which returned +15.17%. Strong stock selection within Biotechnology was outweighed by relative weakness within Pharmaceuticals and MedTech. The following discussion reflects relative performance from the representative account.[1]
Biotechnology was the largest contributor to relative performance during the quarter, with strong stock specific returns from several holdings driven by clinical data catalysts and M&A activity. The M&A environment for biopharma assets with established commercial franchises remains unusually favourable, and we believe the portfolio’s emphasis on commercial-stage biopharma along with innovative, quality earlier stage companies is well-positioned to participate in continued consolidation.
During the quarter, we benefitted from M&A activity in and sold our position in Nuvalent, Inc., an oncology-focused biopharma company following the announcement that GKS would be acquiring the company.
We also exited our position in GeneDx Holdings Corp. (WGS), a leader in genetic testing for rare diseases and paediatrics, that has been pressured by continued concern around pricing and reimbursement dynamics within its genomic testing business. We decided to exit the position during the quarter as our conviction in the business model viability started to waver.
We rotated the capital into biopharma names across the capitalisation spectrum, including Relay Therapeutics, a clinical stage biopharma company with assets targeting both oncology and vascular conditions.
Entering 2026, the Biotechnology industry represented the largest overweight relative to the index, and it remains the largest overweight as of 30/06/2026. We continue to view Biotechnology as the most attractive area within Health Care, with exposure spread across both commercial-stage and development-stage names. Within the group, we are underweight more speculative and non-earning earlier stage names, which face disproportionate pressure from rising rates. M&A remains a tailwind, with large-cap pharma paying substantial premiums for commercial-stage assets.
The Pharmaceuticals industry represented the portfolio’s largest underweight as of year-end and continues to be the largest underweight as of 30/06/2026. We continue to believe that the industry includes many interesting opportunities, and the industry represents a large absolute weight in the portfolio, however we remain underweight given our focus on risk-adjusted opportunities within the industry.
Heading into the third quarter, we see the M&A backdrop for biopharma as even more favourable than it was earlier in the year. The pipeline needs of large pharmaceutical companies are becoming more acute as patent cliffs draw closer, and that urgency is translating into real capital commitments, supported by an accommodative FDA and FTC posture. Importantly, the improving path to standalone commercialisation means the portfolio is less reliant on deal activity to realise value in many of its biopharma holdings, giving us confidence in the underlying thesis whether or not a given name is ultimately acquired. We expect continued deal flow, concentrated in the areas of greatest need for large pharma: oncology, immunology, and rare disease.
Biotechnology remains our highest-conviction sub-industry, but after such a rapid move, we are inclined to add to positions on pullbacks rather than chase strength at current levels. We continue to favour a balance of
mature, commercial-stage compounders alongside select development-stage names with near-term data catalysts, while maintaining discipline against the unprofitable, non-earning biotech cohort that drove much of the quarter’s more speculative gains and that we believe remains vulnerable if the macro backdrop turns less accommodative. Within pharmaceuticals, we continue to see more differentiated innovation in biotech than in the broader pharma group and remain selective, favouring the handful of large-cap names with genuine organic growth drivers over those more reliant on acquired growth to offset patent expirations.
We are becoming incrementally more constructive on medical technology following its extended period of underperformance and valuation compression, and are beginning to selectively add exposure to names we believe have been overly punished for what look like idiosyncratic, rather than structural, issues. We continue to view distributors as an attractive defensive complement within the sector. We are also monitoring the growing use of artificial intelligence in drug discovery and molecule optimisation across the industry, which we believe should improve the long-term probability of success and investability of biopharma research and development, even though we remain cautious about underwriting pure-play AI-adjacent stories directly given the difficulty in isolating true differentiation.
As of 31.07.2026
WELL (Fund)1M-4.26%3M6.59%6M1.24%YTD0.03%12M13.54%3Y-Since Inception (04/04/2019)9.75%
Please note that all performance figures are showing net data. Source: Bloomberg / HANetf. Data as of 31.07.2026
Past performance for the index is in USD. Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Investors should read the prospectus of the Issuer (“Prospectus”) before investing and should refer to the section of the Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in this product. When you invest in ETFs and ETCs, your capital is at risk.
[1] Source: Westfield, FactSet. Data as of 30.06.2026
[2] Ibid
IMPORTANT INFORMATION This document is approved for professional use only.
Communications issued in the UK
The content in this document is issued by HANetf Limited (“HANetf”) and approved by Privium Fund Management (UK) Limited (“Privium”). HANetf is an appointed representative of Privium, which is authorised and regulated by the Financial Conduct Authority. The registered office of Privium is The Shard, 24th Floor, 32 London Bridge Street, London, SE1 9SG
This communication has been prepared for professional investors, but the exchange traded product (“ETCs”) and exchange traded fund (“ETFs”) set out in this communication (“Products”) may be available in some jurisdictions to any investors. Please check with your broker or intermediary that the relevant Product is available in your jurisdiction and suitable for your investment profile.
Disclaimers
Past performance is not a reliable indicator of future performance. The price of the Products may vary and they do not offer a fixed income. This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements. The content of this document is for information purposes and for your internal use only, and does not constitute an investment advice, recommendation, investment research or an offer for sale nor a solicitation of an offer to buy any Product or make any investment.
An investment in an exchange traded product is dependent on the performance of the underlying asset class, less costs, but it is not expected to track that performance exactly. The Products involve numerous risks including among others, general market risks relating to underlying adverse price movements in an Index (for ETFs) or underlying asset class and currency, liquidity, operational, legal and regulatory risks. In addition, in relation to Cryptocurrency ETCs, these are highly volatile digital assets and performance is unpredictable.
Tech Megatrends ETF Report | August 2026
August 2026
Active Global Equity Shariah ETF Report | July 2026
Tech Megatrends ETF Report | July 2026
Canadian Enhanced Income ETF Quarterly Report | July 2026
Preferred Income Quarterly Report | July 2026
Silver ETF Report | July 2026
Active U.S Bond Quarterly Report | July 2026
July 2026
Uranium Miners Monthly Report | July 2026
Ukraine Reconstruction ETF Report | July 2026
Total Return Income ETF Quarterly Report | July 2026
Midstream Energy Dividend ETF Report | July 2026
Making Europe Great Again ETF | July 2026
Gold Miners Screened ETF Report | July 2026
Cat Bond Quarterly Report | July 2026
Future of Defence Report | July 2026
Active U.S Bond Monthly Report | July 2026
Tech Megatrends ETF Report | June 2026
June 2026
Active Global Equity Shariah ETF Report | June 2026
Ukraine Reconstruction ETF Report | June 2026
Midstream Energy Dividend ETF Report | June 2026
Drone ETF Report | June 2026
Making Europe Great Again ETF Report | June 2026
Future of Defence Report | June 2026
Gold Miners Screened ETF Report | June 2026
Gold Miners Screened ETF | May 2026
May 2026
Tech Megatrends ETF Report | May 2026
Active Global Equity Shariah ETF Report | May 2026
Copper Miners ETF Report | May 2026
Future of Defence Report | May 2026
Drone ETF Report | May 2026
Making Europe Great Again ETF | May 2026
Midstream Energy Dividend ETF Report | May 2026
Ukraine Reconstruction ETF Report | May 2026
Total Return Income ETF Quarterly Report | April 2026
April 2026
Tech Megatrends ETF Report | April 2026
Focused Equity Quarterly Report | April 2026
Cat Bond Quarterly Report | April 2026
Gold Miners ETF Report | April 2026
Making Europe Great Again ETF | April 2026
Midstream Energy Dividend ETF Report | April 2026
REX Covered Call Report | April 2026
Defence ETF Report | April 2026
Active U.S. Bond Quarterly Report | March 2026
Middlefield Canadian Enhances Income ETF Quarterly Report | May 2026
Health Care ETF Quarterly Report | April 2026
Tech Megatrends ETF Report | March 2026
March 2026
Active Global Equity Shariah ETF Report | March 2026
Travel ETF Quarterly Report | March 2026
Tech Megatrends ETF Report | February 2026
February 2026
Midstream Energy Dividend ETF Report | February 2026
Uranium Miners ETF Report | February 2026
Make Europe Great Again ETF Report | February 2026
Gold Miners Screened ETF | February 2026
Defence ETF Report | February 2026
Midstream Energy Dividend ETF Report | January 2026
January 2026
Future of Defence Report | January 2026
Copper Miners ETF Report | January 2026
ESGO Gold Miners Screened ETF Report | January 2026
Tech Megatrends ETF Report | January 2026
Middlefield Enhanced Income ETF Quarterly Report | January 2026
Preferred Income Quarterly Report | January 2026
Active U.S. Bond Quarterly Report | January 2026
Total Return Income ETF Quarterly Report | January 2026
Active Global Equity Shariah ETF Report | January 2026
Making Europe Great Again ETF Report | January 2026
Midstream Energy Dividend ETF Report | November 2025
November 2025
Tech Megatrends ETF Report | November 2025
Emerging Markets ETF & India Internet ETF Report | November 2025
EU Carbon Market Monthly Report | November 2025
Travel ETF Quarterly Report | October 2025
October 2025
Active U.S. Bond Quarterly Report | October 2025
Active Global Equity Shariah ETF Report | October 2025
Future of Defence Report | October 2025
EU Carbon Market Monthly Report | October 2025
Health Care ETF Quarterly Report | October 2025
Uranium Miners ETF Report | October 2025
Midstream Energy Dividend ETF Report | October 2025
Tech Megatrends ETF Report | October 2025
Copper Miners ETF Monthly Report | October 2025
Active Global Equity Shariah ETF Report | September 2025
September 2025
EU Carbon Market Monthly Report | September 2025
Emerging Markets ETF & India Internet ETF Report | September 2025
Tech Megatrends ETF Report | September 2025
Midstream Energy Dividend ETF Report | September 2025
Future of Defence Report | September 2025
Crypto Magnified – The leverage update
Tech Megatrends ETF Report | August 2025
August 2025
Emerging Markets ETF & India Internet ETF Report | August 2025
Midstream Energy Dividend ETF Report | August 2025
Active Global Equity Shariah ETF Report | August 2025
Active Global Equity Shariah ETF Report | July 2025
July 2025
Tech Megatrends ETF Report | July 2025
Active U.S. Bond Quarterly Report | July 2025
Uranium Miners ETF Report | July 2025
Midstream Energy Dividend ETF Report | July 2025
Future of Defence Report | July 2025
Travel ETF Quarterly Report | July 2025
Health Care ETF Quarterly Report | July 2025
EU Carbon Market Monthly Report | July 2025
Emerging Markets ETF & India Internet ETF Report | July 2025
Tech Megatrends ETF Report | June 2025
June 2025
Emerging Markets ETF & India Internet ETF Report | June 2025
EU Carbon Market Monthly Report | June 2025
Active Global Equity Shariah ETF Report | June 2025
Midstream Energy Dividend ETF Report | June 2025
Future of Defence Report | June 2025
Uranium Miners ETF Report | June 2025
Copper Monthly Report | June 2025
Active Global Equity Shariah ETF Report | May 2025
May 2025
Midstream Energy Dividend ETF Report | May 2025
Uranium Miners ETF Report | May 2025
Travel ETF Report | May 2025
Emerging Markets ETF & India Internet ETF Report | May 2025
EU Carbon Market Monthly Report | May 2025
Future of Defence Report | May 2025
Tech Megatrends ETF Report | May 2025
Active Global Equity Shariah ETF Report | April 2025
April 2025
ESG Copper Miners ETF Report | April 2025
Tech Megatrends ETF Report | April 2025
Midstream Energy Dividend ETF Report | April 2025
Future of Defence Report | April 2025
Active U.S. Bond Quarterly Report | April 2025
Uranium Miners ETF Report | April 2025
Health Care ETF Quarterly Report | April 2025
Emerging Markets ETF & India Internet ETF Report | April 2025
EU Carbon Market Monthly Report | April 2025
Travel ETF Report | April 2025
Midstream Energy Dividend ETF Report | March 2025
March 2025
Copper Monthly Report | March 2025
Active Global Equity Shariah ETF Report | March 2025
Future of Defence ETF Report | March 2025
Travel ETF Report | March 2025
Uranium Miners ETF Report | March 2025
Emerging Markets ETF & India Internet ETF Report | March 2025
Tech Megatrends ETF Report | March 2025
Emerging Markets ETF & India Internet ETF Report | February 2025
February 2025
EU Carbon Market Monthly Report | February 2025
Uranium Miners ETF Report | February 2025
Tech Megatrends ETF Report | February 2025
Active Global Equity Shariah ETF Report | February 2025
Crypto Report | February 2025
Midstream Energy Dividend ETF Report | February 2025
Travel ETF Report | February 2025
Future of Defence Report | Feburary 2025
Emerging Markets ETF & India Internet ETF Report | January 2025
January 2025
Copper Monthly Report | January 2025
Active U.S Bonds Quarterly Report | January 2025
Midstream Energy Dividend ETF Report | January 2025
EU Carbon Market Monthly Report | January 2025
Uranium Miners ETF Report | January 2025
Active Global Equity Shariah ETF Report | January 2025
Future of Defence Report | January 2025
Travel ETF Report | January 2025
Health Care ETF Quarterly Report | January 2025
ESG Gold ETF Report | January 2025
Crypto Report | January 2025
Active Global Equity Shariah ETF Report | December 2024
December 2024
Emerging Markets ETF & India Internet ETF Report | December 2024
Midstream Energy Dividend ETF Report | December 2024
Future of Defence Report | December 2024
Travel ETF Report | December 2024
EU Carbon Market Monthly Report | December 2024
Tech Megatrends ETF Report | December 2024
ESG Gold ETF Report | December 2024
EU Carbon Market Monthly Report | November 2024
November 2024
Emerging Markets ETF & India Internet ETF Report | November 2024
Midstream Energy Dividend ETF Report | November 2024
Active Global Equity Shariah ETF Report | November 2024
Future of Defence Report | November 2024
Travel ETF Report | November 2024
ESG Gold ETF Report | November 2024
Tech Megatrends ETF Report | November 2024
Uranium Miners ETF Report | October 2024
October 2024
EU Carbon Market Monthly Report | October 2024
Health Care ETF Quarterly Report | October 2024
Midstream Energy Dividend ETF Report | October 2024
Emerging Markets ETF & India Internet ETF Report | October 2024
Active Global Equity Shariah ETF Report | October 2024
Crypto Report | October 2024
ESG Gold ETF Report | October 2024
Tech Megatrends ETF Report | October 2024
Future of Defence Report | October 2024
Travel ETF Report | October 2024
Emerging Markets ETF & India Internet ETF Report | September 2024
September 2024
Uranium Miners ETF Report | September 2024
Active Global Equity Shariah ETF Report | September 2024
Crypto Report | September 2024
Midstream Energy Dividend ETF Report | September 2024
Future of Defence Report | September 2024
Travel ETF Report | September 2024
ESG Gold ETF Report | September 2024
Tech Megatrends ETF Report | September 2024
Energy Transition Materials ETF Report | August 2024
August 2024
Tech Megatrends ETF Report | August 2024
Emerging Markets ETF & India Internet ETF Report | August 2024
Defence and Aerospace ETF Report | August 2024
Midstream Energy Dividend ETF | August 2024
Active Global Equity Shariah ETF Report | August 2024
ESG-Screened Gold Miners ETF Report | August 2024
Crypto Report | August 2024
Active Global Equity Shariah ETF Report | July 2024
July 2024
Emerging Markets ETF & India Internet ETF Report | July 2024
Midstream Energy Dividend ETF | July 2024
Defence and Aerospace ETF Report | July 2024
Uranium Miners ETF Report | July 2024
Energy Transition Materials ETF Report | July 2024
Crypto Report | July 2024
ESG-Screened Gold Miners ETF Report | July 2024
Tech Megatrends ETF Report | July 2024
Midstream Energy Dividend ETF | June 2024
June 2024
Active Global Equity Shariah ETF Screened Report | June 2024
Emerging Markets ETF & India Internet ETF Report | June 2024
Tech Megatrends ETF Report | June 2024
Uranium Miners ETF Report | June 2024
Energy Transition Material ETF Report | June 2024
Future of Defence Report | June 2024
ESG-Screened Gold Miners ETF Report | June 2024
Crypto Report | June 2024
5G Digital Infrastructure ETF Report | May 2024
May 2024
Emerging Markets ETF & India Internet ETF Report | May 2024
Midstream Energy Dividend ETF Report | May 2024
Energy Transition Material ETF Report | May 2024
Crypto Report | May 2024
Global Equity Active Shariah ETF Screened Report | May 2024
Tech Megatrend ETF Report | May 2024
Future of Defence Report | May 2024
ESG-Screened Gold Miners ETF Report | May 2024
Global Equity Active Shariah ETF Screened Report | April 2024
April 2024
Crypto Report | April 2024
5G Digital Infrastructure ETF Report | April 2024
Emerging Markets ETF & India Internet ETF Report | April 2024
Tech Megatrends ETF Report | April 2024
Midstream Energy ETF | April 2024
Energy Transition Material ETF Report | April 2024
Uranium Miners ETF Report | April 2024
ESG-Screened Gold Miners ETF Report | April 2024
Future of Defence ETF Report | Apr 2024
5G Digital Infrastructure ETF Report | Mar 2024
March 2024
Tech Megatrend ETF Report | March 2024
Airlines ETF Report | Mar 2024
Midstream Energy ETF Report | Mar 2024
Future of Defence ETF Report | Mar 2024
Emerging Markets and India Internet ETF Report | Mar 2024
Energy Transition Materials ETF Report | Mar 2024
Uranium Miners ETF Report | Mar 2024
Decarbonisation Enablers ETF Report | Mar 2024
Crypto Report | Mar 2024
Metaverse ETF Report | March 2024
Global Equity Shariah ETF Screened Report | Mar 2024
ESG Gold Mining ETF Report | Mar 2024
ESG Gold Mining ETF Report | Feb 2024
February 2024
Energy Transition Materials ETF Report | Feb 2024
Global Equity Active Shariah ETF Screened Report | Feb 2024
Decarbonisation Enablers ETF Report | Feb 2024
EV Charging Infrastructure ETF Report | Feb 2024
Midstream Energy ETF Report | Feb 2024
Uranium Miners ETF Report | Feb 2024
Future of Defence ETF Report | Feb 2024
Crypto Report | Feb 2024
Cloud Technology ETF Report | Feb 2024
Digital Assets Report | Feb 2024
Tech Megatrend ETF Report | Feb 2024
Airlines ETF Report | Feb 2024
Monthly Global Equity Active Shariah Screened Report | January 2024
January 2024
Monthly Decarbonisation Enablers Report | January 2024
Emerging Markets ETF Monthly Report | January
Digital Infrastructure ETF Monthly Report | January
EV Charging Infrastructure ETF Monthly Report | January
Crypto Monthly Report | January
Islamic Equity Monthly Report | December
December 2023
Midstream Energy Monthly Report | December
Airlines ETF Monthly Report | December
Future of Defence ETF Monthly Report | December
ESG-Screened Gold Miners ETF Monthly Report | December
Emerging Markets ETF Monthly Report | November
November 2023
Energy Transition Materials ETF | Monthly Report
Future of Defence ETF Monthly Report | November
Midstream Energy ETF Monthly Report | November
Travel ETF Monthy Report | November
ESG Gold Mining ETF Monthly Report | November 2023
Future of Finance ETF Monthly Report | November
Shariah ETF Monthly Report | November
Airlines Monthly Report | November
Digital Infrastructure ETF Monthly Report | November
Crypto Monthly Report | November
Digital Assets Monthly Report | November
Select Your Country
Select Your Investor Type
Choose a brokerage
Choose a product
You are now leaving HANetf's website and accessing a third-party website. HANetf may provide access to information, products, or services offered on websites that are owned or operated by other companies ("third-party websites"). We provide this access through the use of hyperlinks that automatically move you from a HANetf website to the third-party site.
While we do our best to provide you with helpful, trustworthy resources, HANetf cannot endorse, approve, or guarantee information, products, services, or recommendations provided at a third-party website. Since we may not always know when information on a linked site changes, HANetf is not responsible for the content or accuracy of any third-party website. HANetf shall not be responsible for any loss or damage of any sort resulting from the use of a link on its websites nor will it be liable for any failure of products or services advertised or provided on these linked sites.
HANetf offers you links on an "as is" basis. When you visit a third-party website by using a link on a HANetf site, you will no longer be protected by the HANetf privacy policy or security practices. The data collection, use, and protection practices of the linked site may differ from the practices of HANetf sites. You should familiarize yourself with the privacy policy and security practices of the linked website. Those are the policies and practices that will apply to your use of the linked website, not the HANetf policies and practices.
Here are some tips to help you tell if you have left a HANetf website:
Important Notice: HANetf is a provider of Exchange Traded Funds (ETFs) and Exchange Traded Commodities (ETCs). We do not sell investment products directly to individual investors. Our funds are available through regulated investment platforms and brokers. Our only official website is www.hanetf.com. Any other domain is not affiliated with or authorised by HANetf in any way. If you suspect fraudulent activity, please contact your local financial regulator and/or the police and report the website or individual involved.